Discontinuing oral bisphosphonate therapy during dental extraction does not prevent osteonecrosis of the jaw: A multicenter retrospective study of 341 patients with propensity score matching analysis

Kawakita, Akiko; Yanamoto, Souichi; Morishita, Kota; Naruse, Tomofumi; Hayashida, Shinsaku; Soutome, Sakiko; Rokutanda, Satoshi; Inokuchi, Satoshi; Matsuo, Takemitsu; Umeda, Masahiro

doi:10.1016/j.ajoms.2017.07.008

Cited by 12 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The PRISMA flowchart is presented in Figure 1. We included nine studies in our review [12][13][14][15][16][17][18][19][20]. All studies were observational and one study was an interventional study [20].…”

Section: Resultsmentioning

confidence: 99%

“…All studies were observational and one study was an interventional study [20]. Among the observational studies, two were prospective [12,16] and six were retrospective studies [13][14][15][17][18][19]. The characteristics of the included studies comprised descriptive data, such as study characteristics of the study population, type of ARs, duration of AR treatment, MRONJ characteristics, drug holiday characteristics, and the final outcome, and are summarized in Table 1.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Antiresorptive Drug Holidays on Medication-Related Osteonecrosis of the Jaw: A Systematic Review and Meta-Analysis

Aboalela¹,

Farook²,

Alqahtani³

et al. 2022

Cureus

View full text Add to dashboard Cite

The objective of this study is to evaluate the effectiveness of discontinuing high-dose antiresorptive (AR) therapy in reducing the risk of medication-related osteonecrosis of the jaw (MRONJ) in patients treated with AR medications and undergoing dentoalveolar surgery or tooth extractions.The review was carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations. A literature search was conducted using the databases MEDLINE, Embase, Web of Science, Scopus, and Cochrane Central Register of Controlled Trials (CENTRAL) from inception till the 1st of April, 2022. Both observational and interventional studies that evaluated the effect of AR drug holiday in the development of MRONJ in patients receiving AR medications and who require dentoalveolar surgical procedures were included. Trials published as abstracts, case reports, case series, non-systematic reviews, and others were excluded. All findings were reported as odds ratios (ORs) and corresponding 95% confidence intervals (CIs). The Newcastle-Ottawa Quality Assessment Scale was used to evaluate the methodological quality assessment, and the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach was used to evaluate the quality of the evidence.Eight articles (6808 subjects) were included for analysis. Of the participants, 4847 cases (drug holiday group) were compared to 1961 controls (non-drug holiday group). Based on the random effects model, the pooled summary OR was 0.73 (95% CI: 0.51-1.06) for the drug holiday group compared to the non-drug holiday group. In other words, the drug holiday group was not significantly different from the non-drug holiday group in the development of MRONJ following a tooth extraction procedure (p = 0.10). The statistical heterogeneity was low across all studies (I 2 = 13%, p = 0.33).Within the limits of the available evidence, our findings revealed that drug holidays with AR will not minimize the risk of MRONJ and thus cannot be advised. It may be possible to arrive at more definitive conclusions from large prospective studies and randomized trials of good quality.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

The Effect of Antiresorptive Drug Holidays on Medication-Related Osteonecrosis of the Jaw: A Systematic Review and Meta-Analysis

Aboalela¹,

Farook²,

Alqahtani³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…Kawakita et al. 6 and Hasegawa et al. 7 reported that a 3-month drug holiday before tooth extraction in patients receiving low-dose oral BP did not reduce the risk of developing MRONJ.…”

Section: Introductionmentioning

confidence: 99%

Drug holiday of high-dose denosumab and recovery from osteoclast inhibition using immunohistochemical investigation of 7 patients with medication-related osteonecrosis of the jaw undergoing segmental mandibulectomy

Sawada¹,

Sakamoto²,

Kirihigashi³

et al. 2023

Journal of Dental Sciences

View full text Add to dashboard Cite

“…Se ha reportado que las extracciones dentales, implantes dentales, cirugía dental, tratamiento periodontal y trauma ocasionado por prótesis dental pueden iniciar un proceso de BRONJ en pacientes en tratamiento con BP 23,24 . Ante la relación establecida entre los BP y BRONJ la AAOMS recomienda suspender los BP orales desde 3 meses antes de un tratamiento dental invasivo y hasta 3 meses después, sin que al parecer exista mayor evidencia científica 25 , ni resultados clínicos que demuestren su efectividad 26 .…”

Section: Introductionunclassified

Osteonecrosis of the jaw associated to biphosponates in Cali-Colombia

Arcila¹,

Llano²

2020

Rev Estomatol

View full text Add to dashboard Cite

Background: After more than 15 years of the first report of osteonecrosis associated with bisphosphonate (BP), still cases related to BP and other medications continue to be reported and there is an alert about the increase in the number of prescriptions. The need for both patients and students and health professionals to be familiar with medications, pathology, prevention and treatment measures has been highlighted. Aim: To characterize patients with osteonecrosis in the maxilla associated to bisphosphonate (BRONJ), from Cali, Colombia. Materials and Methods: A structured survey was conducted of 32 maxillofacial surgeons from the city of Cali, Colombia, where different topics related to affected patients and the development of the pathology such as age and gender of patients, type of medication, time of study were asked. administration, exposed bone, etc. Results: Thirty-two maxillofacial surgeons answered the survey with a total of 8 cases, it was found that 6 corresponded to women and 2 to men and the age was over 44 years; 4 of the treatments were oral prescription and 4 intravenous; the majority of cases were presented in the jaw (88%) and 6 cases (75%) presented bone exposure. Conclusions: Osteonecrosis associated with bisphosphonates is a situation that still occurs and could increase its incidence due to the increase in the number of prescriptions for osteoporosis medications, it is necessary that the patient community and health staff know More about this situation.

show abstract

Discontinuing oral bisphosphonate therapy during dental extraction does not prevent osteonecrosis of the jaw: A multicenter retrospective study of 341 patients with propensity score matching analysis

Cited by 12 publications

References 20 publications

The Effect of Antiresorptive Drug Holidays on Medication-Related Osteonecrosis of the Jaw: A Systematic Review and Meta-Analysis

The Effect of Antiresorptive Drug Holidays on Medication-Related Osteonecrosis of the Jaw: A Systematic Review and Meta-Analysis

Drug holiday of high-dose denosumab and recovery from osteoclast inhibition using immunohistochemical investigation of 7 patients with medication-related osteonecrosis of the jaw undergoing segmental mandibulectomy

Osteonecrosis of the jaw associated to biphosponates in Cali-Colombia

Contact Info

Product

Resources

About